---
document_datetime: 2025-07-16 13:13:28
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/javlor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: javlor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5813916
conversion_datetime: 2025-12-22 20:04:38.181883
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Javlor

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 16/07/2025                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000272416   | PRODUCTS - C.I.z Other variation - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - Type IB - Change in the section 4.7 of the SmPC to align the wording of adverse events with approved section 4.8 C.I.z - Type IB - To update MedDRA preferred term for \"Venous thrombosis\" and to specify that the frequency of 'venous thrombosis' includes the frequency of 'phlebitis'. Additionally, Marketing Authorisation Holder is taking opportunity to align Section 6.5 of the SmPC and relevant section in PL with the approved module 3 for the colour of the glass vial and of the bonnets.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|